About one in five patients on denosumab developed low calcium, a reminder that strong therapies need careful monitoring.
Denosumab is a valuable medication for osteoporosis, and I prescribe it with confidence. But an April 2026 study is a useful reminder that powerful treatments deserve careful attention, before and during use.
Among 303 adults on denosumab, about 21% developed low blood calcium. Most cases were mild, which is reassuring. But notably, this happened even among people already taking calcium and vitamin D. The risk was higher in those using diuretics and those with low vitamin D levels. The authors' conclusion was sensible: assess each person individually before starting, and monitor along the way.
I bring this up not to frighten anyone away from an effective therapy, but to underline a principle I hold across all of bone care: this is not “set and forget” medicine.
Checking vitamin D and calcium before treatment, and keeping an eye on them during it, is exactly the kind of unglamorous diligence that keeps a good treatment safe.
If you're on denosumab, or considering it, it's worth confirming that your vitamin D and calcium are being looked after as part of the plan. Good monitoring is part of good treatment, and it's a fair thing to ask about.
Wondering about your own bone health?
Book a ConsultationAmong 303 adults on denosumab for osteoporosis, about 21% developed low blood calcium (mostly mild); diuretic use and low vitamin D were key risk factors, even among those taking calcium and vitamin D, supporting individualized pre-treatment assessment and monitoring.
